CRVO
CervoMed Inc.
There isn't enough reported data to score CRVO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CRVO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
CRVO's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRVO PE Valuation
CRVO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CRVO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.78 | +$0.09 |
| Q2 2026 | -$3.23 | -$0.65 |
| Q1 2026 | -$3.29 | -$1.14 |
| Q4 2025 | -$2.99 | -$0.99 |
CRVO lost $2.78 per share over the past year, about the same as its loss the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRVO on earnings quality, reporting a profit while its opponent remains loss making.
CRVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $8.7K | -100% |
| Q3 2025 | $322.6K | -83% |
| Q2 2025 | $1.8M | -47% |
| Q1 2025 | $1.9M | -18% |
| Q4 2024 | $2.2M | -13% |
| Q3 2024 | $1.9M | +27% |
CRVO's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -95479% | -95144 points |
| Q3 2025 | -2494% | -2216 points |
| Q2 2025 | -376% | -285 points |
| Q1 2025 | -277% | -166 points |
| Q4 2024 | -335% | -235 points |
| Q3 2024 | -278% | -103 points |
| Q2 2024 | -91% | N/A |
| Q1 2024 | -111% | N/A |
CRVO's operating margin was −95479% last quarter, down 95144 points from the same quarter a year ago, near the bottom of its range since 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CRVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.1M | +$1.4M |
| Q2 2026 | -$6.9M | -$403.7K |
| Q1 2026 | -$8M | -$4.1M |
| Q4 2025 | -$6.6M | +$1.5M |
| Q3 2025 | -$6.5M | -$1.6M |
| Q2 2025 | -$6.5M | -$4.3M |
| Q1 2025 | -$3.9M | -$2.5M |
| Q4 2024 | -$8.1M | -$5.5M |
CRVO has burned cash in almost every quarter: −$27M over the past year, against −$25M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CRVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +48% | +4.9M shares |
| 1 year | +63% | +5.9M shares |
| 3 years | +1012% | +13.8M shares |
| 5 years | +3177% | +14.7M shares |
CRVO has 15M diluted shares, up 63% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRVO Net Leverage
CRVO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.8 | Neutral |
| Stochastic | 10.9 | Oversold |
CRVO's weekly RSI is 38 (neutral) and its Stochastic is 11 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRVO PE vs Healthcare Sector
CRVO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.27 | 19% below |
| 20 week MA | $2.60 | 30% below |
| 50 week MA | $4.00 | 54% below |
| 100 week MA | $5.50 | 67% below |
| 200 week MA | $8.45 | 78% below |
CRVO is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRVO on trend strength, trading above more of its moving averages.
CRVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $30.0 | $56.3 | +88% |
| 2021 | $56.3 | $29.3 | -48% |
| 2022 | $29.3 | $8.40 | -71% |
| 2023 | $8.40 | $7.63 | -9.2% |
| 2024 | $7.63 | $2.40 | -69% |
| 2025 | $2.40 | $8.08 | +237% |
| 2026 YTD | $8.08 | $1.83 | -77% |
CRVO's yearly returns have swung widely, from +237% in 2025 to −71% in 2022. It's down 77% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRVO on returns for 2026, with the stronger performance.